Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trial
TL;DR Summary
Eli Lilly's obesity drug has outperformed a rival in a direct clinical trial, potentially boosting the company's market position. Jim Cramer discusses the implications for Eli Lilly's stock, suggesting potential growth opportunities following the trial results.
- Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next CNBC
- Zepbound results in more weight loss than Wegovy in trial, Eli Lilly says NBC News
- Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk Investor's Business Daily
- Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says CNN
- Zepbound tops Wegovy for weight loss in Eli Lilly study The Associated Press
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
68%
111 → 36 words
Want the full story? Read the original article
Read on CNBC